SRS Capital Advisors Inc. Sells 153 Shares of Eli Lilly and Company (NYSE:LLY)

SRS Capital Advisors Inc. lessened its stake in shares of Eli Lilly and Company (NYSE:LLY) by 7.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,997 shares of the company’s stock after selling 153 shares during the quarter. SRS Capital Advisors Inc.’s holdings in Eli Lilly and Company were worth $1,164,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Lipe & Dalton bought a new position in shares of Eli Lilly and Company in the fourth quarter valued at $26,000. Thompson Investment Management Inc. bought a new stake in Eli Lilly and Company during the 3rd quarter worth approximately $27,000. Legacy Financial Group LLC purchased a new stake in shares of Eli Lilly and Company in the third quarter worth approximately $35,000. Optiver Holding B.V. bought a new position in shares of Eli Lilly and Company in the third quarter valued at approximately $36,000. Finally, Family CFO Inc purchased a new position in shares of Eli Lilly and Company during the third quarter valued at approximately $40,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on LLY shares. Morgan Stanley increased their price target on Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research report on Friday, February 16th. TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Barclays upped their price objective on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 7th. BMO Capital Markets lifted their target price on shares of Eli Lilly and Company from $900.00 to $1,001.00 and gave the stock an “outperform” rating in a research report on Wednesday. Finally, Wells Fargo & Company upped their target price on Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $757.95.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock traded down $18.74 during trading on Thursday, hitting $758.01. The stock had a trading volume of 1,864,490 shares, compared to its average volume of 3,053,041. The firm has a market cap of $720.23 billion, a price-to-earnings ratio of 111.71, a P/E/G ratio of 1.58 and a beta of 0.37. Eli Lilly and Company has a 12 month low of $414.31 and a 12 month high of $800.78. The business’s 50-day moving average is $762.03 and its 200 day moving average is $669.96. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Tuesday, April 30th. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.53 by $0.05. The firm had revenue of $8.77 billion for the quarter, compared to analysts’ expectations of $8.94 billion. Eli Lilly and Company had a return on equity of 59.28% and a net margin of 17.08%. The company’s revenue was up 26.0% compared to the same quarter last year. During the same quarter last year, the firm posted $1.62 EPS. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 13.5 earnings per share for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.